Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Direct targeted therapy for MLL-fusion-driven high-risk acute leukaemias.
Cantilena S, Gasparoli L, Pal D, Heidenreich O, Klusmann JH, Martens JHA, Faille A, Warren AJ, Karsa M, Pandher R, Somers K, Williams O, de Boer J. Cantilena S, et al. Among authors: karsa m. Clin Transl Med. 2022 Jun;12(6):e933. doi: 10.1002/ctm2.933. Clin Transl Med. 2022. PMID: 35730653 Free PMC article.
CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements.
Somers K, Chudakova DA, Middlemiss SM, Wen VW, Clifton M, Kwek A, Liu B, Mayoh C, Bongers A, Karsa M, Pan S, Cruikshank S, Scandlyn M, Hoang W, Imamura T, Kees UR, Gudkov AV, Chernova OB, Haber M, Norris MD, Henderson MJ. Somers K, et al. Among authors: karsa m. Oncotarget. 2016 Jul 19;7(29):46067-46087. doi: 10.18632/oncotarget.10022. Oncotarget. 2016. PMID: 27317766 Free PMC article.
A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.
Somers K, Wen VW, Middlemiss SMC, Osborne B, Forgham H, Jung M, Karsa M, Clifton M, Bongers A, Gao J, Mayoh C, Raoufi-Rad N, Kusnadi EP, Hannan KM, Scott DA, Kwek A, Liu B, Flemming C, Chudakova DA, Pandher R, Failes TW, Lim J, Angeli A, Osterman AL, Imamura T, Kees UR, Supuran CT, Pearson RB, Hannan RD, Davis TP, McCarroll J, Kavallaris M, Turner N, Gudkov AV, Haber M, Norris MD, Henderson MJ. Somers K, et al. Among authors: karsa m. Oncogene. 2019 May;38(20):3824-3842. doi: 10.1038/s41388-018-0666-5. Epub 2019 Jan 22. Oncogene. 2019. PMID: 30670779 Free PMC article.
Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K, Kosciolek A, Bongers A, El-Ayoubi A, Karsa M, Mayoh C, Wadham C, Middlemiss S, Neznanov N, Kees UR, Lock RB, Gudkov A, Sutton R, Gurova K, Haber M, Norris MD, Henderson MJ. Somers K, et al. Among authors: karsa m. Int J Cancer. 2020 Apr 1;146(7):1902-1916. doi: 10.1002/ijc.32582. Epub 2019 Aug 8. Int J Cancer. 2020. PMID: 31325323 Free article.
Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia.
Somers K, Evans K, Cheung L, Karsa M, Pritchard T, Kosciolek A, Bongers A, El-Ayoubi A, Forgham H, Middlemiss S, Mayoh C, Jones L, Gupta M, Kees UR, Chernova O, Korotchkina L, Gudkov AV, Erickson SW, Teicher B, Smith MA, Norris MD, Haber M, Lock RB, Henderson MJ. Somers K, et al. Among authors: karsa m. Leukemia. 2020 Jun;34(6):1524-1539. doi: 10.1038/s41375-019-0683-6. Epub 2019 Dec 17. Leukemia. 2020. PMID: 31848452 Free PMC article.
Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma.
Xiao L, Somers K, Murray J, Pandher R, Karsa M, Ronca E, Bongers A, Terry R, Ehteda A, Gamble LD, Issaeva N, Leonova KI, O'Connor A, Mayoh C, Venkat P, Quek H, Brand J, Kusuma FK, Pettitt JA, Mosmann E, Kearns A, Eden G, Alfred S, Allan S, Zhai L, Kamili A, Gifford AJ, Carter DR, Henderson MJ, Fletcher JI, Marshall G, Johnstone RW, Cesare AJ, Ziegler DS, Gudkov AV, Gurova KV, Norris MD, Haber M. Xiao L, et al. Among authors: karsa m. Clin Cancer Res. 2021 Aug 1;27(15):4338-4352. doi: 10.1158/1078-0432.CCR-20-2357. Epub 2021 May 16. Clin Cancer Res. 2021. PMID: 33994371 Free PMC article.
Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia.
Karsa M, Ronca E, Bongers A, Mariana A, Moles E, Failes TW, Arndt GM, Cheung LC, Kotecha RS, Kavallaris M, Haber M, Norris MD, Henderson MJ, Xiao L, Somers K. Karsa M, et al. Front Oncol. 2022 Jan 20;11:779859. doi: 10.3389/fonc.2021.779859. eCollection 2021. Front Oncol. 2022. PMID: 35127484 Free PMC article.
The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression.
Xiao L, Karsa M, Ronca E, Bongers A, Kosciolek A, El-Ayoubi A, Revalde JL, Seneviratne JA, Cheung BB, Cheung LC, Kotecha RS, Newbold A, Bjelosevic S, Arndt GM, Lock RB, Johnstone RW, Gudkov AV, Gurova KV, Haber M, Norris MD, Henderson MJ, Somers K. Xiao L, et al. Among authors: karsa m. Front Oncol. 2022 May 23;12:863329. doi: 10.3389/fonc.2022.863329. eCollection 2022. Front Oncol. 2022. PMID: 35677155 Free PMC article.
Delivery of PEGylated liposomal doxorubicin by bispecific antibodies improves treatment in models of high-risk childhood leukemia.
Moles E, Howard CB, Huda P, Karsa M, McCalmont H, Kimpton K, Duly A, Chen Y, Huang Y, Tursky ML, Ma D, Bustamante S, Pickford R, Connerty P, Omari S, Jolly CJ, Joshi S, Shen S, Pimanda JE, Dolnikov A, Cheung LC, Kotecha RS, Norris MD, Haber M, de Bock CE, Somers K, Lock RB, Thurecht KJ, Kavallaris M. Moles E, et al. Among authors: karsa m. Sci Transl Med. 2023 May 17;15(696):eabm1262. doi: 10.1126/scitranslmed.abm1262. Epub 2023 May 17. Sci Transl Med. 2023. PMID: 37196067
18 results